Tamura’s study was a phase II and open-label clinical trial, assessing nivolumab (240 mg every two weeks) in 20 patients with advanced/recurrent cervical cancers who received at least one chemotherapy regimen [PD-L1 positivity expression, tumor proportion score (TPS) ≥1%]. Here, CD274 is linked to neoplasm.